Cloud PR Wire

PathAI launches six additional oncology indications for PathExplore, an AI-powered pathology panel for spatial analysis of the tumor microenvironment

–News Direct–

PathAI, a global leader in AI-powered pathology, today announced the launch of six additional oncology indications for PathExplore, the worlds first structured, standardized and scalable panel for characterization of the tumor microenvironment (TME) from hematoxylin and eosin (H&E)-stained whole-slide images (WSIs). The additional indications are ovarian, bladder, liver, small cell lung, lymphoma, and head and neck cancers. PathExplore first launched in April 2023 with 8 indications, including non-small cell lung, breast, colorectal, skin, gastric, prostate, kidney, and pancreatic cancers. With this expansion, PathExplore human interpretable features (HIFs) will now be available across 14 oncology indications to accelerate the next phase of precision oncology.

The last decade has seen significant strides in oncology drug development, but challenges remain many cancer patients do not respond to available treatments, and many arent eligible for potentially transformative therapies because of a lack of actionable biomarkers. Distinct cell populations, tissue structures, and their spatial distributions across the TME represent some of the most promising areas of oncology research, however; traditional approaches are unable to access the full resolution of histopathology data at scale.

Pathology is the only data modality to define and quantify morphological changes resulting from treatment or disease progression , said Andy Beck, M.D., Ph.D., chief executive officer and co-founder of PathAI. PathExplore enables researchers and drug developers to effortlessly investigate standard characteristics of the TME, such as the abundance of tumor-infiltrating lymphocytes, as well as spatial characteristics that were previously impossible to measure such as the ratio of lymphocytes to fibroblasts near the epithelial-stromal interface.

Since launch, PathExplore has established itself as the gold-standard in AI-powered digital pathology for oncology drug development. PathAI has partnered with over 50 pharma, biotech, academic, and laboratory partners to analyze >150,000 WSIs, resulting in 50+ publications and presentations.

PathExplore represents a tremendous leap forward in biological research, bypassing long standing constraints of many existing modalities by combining the widespread availability of H&E with the unprecedented resolution of AI, said Mike Montalto, PhD, chief scientific officer at PathAI. By expanding the availability of PathExplores structured pathology data into new disease areas, were empowering drug developers to continue to uncover insights that go beyond existing biomarkers.

To learn more about PathExplore, download our ebook that highlights real-world applications of AI-powered pathology solutions including PathExplore, in various stages of drug development programs.

PathExplore is For Research Use Only. Not for use in diagnostic procedures.

About PathAI

PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and laboratory use. Their AI-powered models are rigorously trained and validated with data from more than 15 million annotations and are used to optimize the analysis of pathology samples to improve efficiency and accuracy, while also accelerating drug development. PathAI is headquartered in Boston, MA, and manages a CAP/CLIA-certified laboratory in Memphis, TN. For more information, please visit www.pathai.com.

Contact Details

SVM Public Relations and Marketing Communications

Maggie Naples

+1 401-490-9700

pathai@svmpr.com

Company Website

https://www.pathai.com/

View source version on newsdirect.com: https://newsdirect.com/news/pathai-launches-six-additional-oncology-indications-for-pathexplore-an-ai-powered-pathology-panel-for-spatial-analysis-of-the-tumor-microenvironment-623215494

PathAI

comtex tracking

COMTEX_447055990/2655/2024-01-30T09:58:47

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Fast Amplify journalist was involved in the writing and production of this article.